Turkey's Pharma Industry In Crisis

6 October 1996

Press reports in the Turkish capital Ankara have recorded the nation's pharmaceutical employers' union as saying that Turkey's pharmaceutical industry has been making losses for the past three years. According to the EBA Newsletter, the union's chairman, Kaya Turgut, is reported as saying that the industry faced losses of 4.4% in 1994, 7.9% in 1995 and 9.9% in the past five months of this year.

Mr Turgut blamed the Ministry of Health for the losses, claiming that many local drug producers will be forced to close down and consign their businesses to foreign investors.

At a press conference, Mr Turgut suggested that the proportion of total drugs supplied to the Turkish market by local producers is falling, and the sector is receiving little government support. One economics expert at the press meeting described the state of the Turkish drugs manufacturing sector as "highly critical," and warned that it could be close to collapse.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight